Amid new government directives around diversity, equity, and inclusion programs in the US, our April issue explores the pivots and adjustments pharma and healthcare interests are making to maintain the progress of such efforts in advancing clinical research.
Related Posts
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
Credit: magicmine | stock.adobe.com Key takeaways The expanded FDA approval of Farapulse introduces a non-thermal ablation option for persistent AF,…
AI-Powered Non-Interventional Research Delivers What DCTs Promised
Image Credit: © Kaikoro – stock.adobe.com Summary AI-powered, unified digital platforms are streamlining non-interventional studies by removing site dependencies, accelerating…
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
Image Credit: © JHVEPhoto – stock.adobe.com The FDA has approved Johnson & Johnson’s IMAAVY (nipocalimab-aahu) for the treatment of treatment…